Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma

Main Article Content

John Kirkwood
Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

Reinhard Dummer
Department of Dermatology, University Hospital Z?rich Skin Cancer Center, Z?rich, Switzerland

Axel Hauschild
Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany

Mario Santinami
Melanoma and Sarcoma Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Victoria Atkinson
Division of Cancer Services, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Greenslopes, QLD, Australia

Vanna Sileni
Melanoma Cancer Unit, Department of Experimental and Clinical Oncology, Veneto Oncology Institute-IRCCS, Padova, Italy

James Larkin
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK

Marta Nyakas
Department of Cancer, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway

Andrew Haydon
Melanoma Service, Department of Medical Oncology, The Alfred Hospital, Melbourne, VIC, Australia

Caroline Dutriaux
Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, H?pital Saint-Andr?, Bordeaux, France

Jacob Schachter
Division of Oncology, Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Caroline Robert
Dermatology Service and Melanoma Research Unit, Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France

Laurent Mortier
Service de Dermatologie, Universit? de Lille, INSERM U 1189, Lille, France

Hiya Banerjee
Clinical Development and Analytics, Novartis Pharmaceuticals Corporation, East Hanover, NJ,

Tomas Haas
Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland

Monique Tan
Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

Mike Lau
Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland

Dirk Schadendorf
Department of Dermatology, Comprehensive Cancer Center (Westdeutsches Tumorzentrum), University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany

Georgina Long
Department of Medical Oncology, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia

Mario Mandala
Department of Oncology and Hematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

Keywords

Melanoma, BRAF inhibitor, MEK inhibitor, Adjuvant Therapy, Survival Time

Abstract

Abstract not available.

References

1. Hauschild A, et al. ASCO 2020 [abstract 10001].

2. Weber JS, et al. ESMO 2019 [abstract 1310O].

3. Eggermont AM, et al. ASCO 2020 [abstract 10000].

4. A'Hern RP. J Clin Oncol. 2016;34(28):3474-3476.

5. Kim DH, et al. JAMA Cardiol. 2017;2(11):1179-1180.

6. Pak K, et al. JAMA Oncol. 2017;3(12):1692-1696.

7. Uno H, et al. J Clin Oncol. 2014;32(22):2380-2385.

8. Othus M, et al. Clin Cancer Res. 2012;18(14):3731-3736.

9. Huang L, et al. Cancer. 2008;112(10):2289-2300.

Article Sidebar

Poster PDF
Published
2021-01-01
DOI: https://doi.org/10.25251/skin.5.supp.2

Article Details

How to Cite
[1]
2021. Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s2. DOI:https://doi.org/10.25251/skin.5.supp.2.
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Poster Presentations from WC21 Clinical Dermatology Conference®: Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2